• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - inflammation - Page 2
Tag:

inflammation

Health

Eating oranges daily may shift lipid patterns in fatty liver disease

by Chief Editor April 20, 2026
written by Chief Editor

Beyond the Plate: The Future of Fighting Fatty Liver with Precision Nutrition

For decades, the medical advice for fatty liver disease was simple, if frustrating: “lose weight and eat better.” But as we move deeper into the era of personalized medicine, we are discovering that the fight against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is far more nuanced than a simple calorie deficit.

Recent research, including trials on the impact of specific citrus varieties like “Navelina” oranges, suggests that we are on the cusp of a shift. We are moving away from generic dietary guidelines and toward lipidomics—the high-definition mapping of fats in our blood to tailor nutrition to the individual.

Did you know? MASLD (formerly known as NAFLD) is now recognized not just as a liver issue, but as a systemic metabolic condition. This name change reflects a growing understanding that the liver is often the “canary in the coal mine” for overall metabolic health.

The Rise of Lipidomics: Seeing the Full Picture

Traditionally, doctors looked at a “lipid panel”—total cholesterol, LDL, and HDL. While useful, this is like looking at a forest from a satellite; you see the green, but you miss the individual trees.

Lipidomics changes the game. It allows scientists to identify hundreds of specific lipid species. As seen in recent clinical trials, we can now track how specific nutrients shift the ratio of pro-inflammatory fatty acids (like arachidonic acid) to anti-inflammatory ones (like eicosapentaenoic acid or EPA).

The future trend here is clear: biomarker-driven dieting. Instead of a one-size-fits-all Mediterranean diet, patients may soon receive a “lipid fingerprint” analysis that tells them exactly which polyphenols or omega-3 sources their specific liver needs to reduce inflammation.

Nutraceuticals: Food as Targeted Therapy

We are seeing a transition from “healthy eating” to “nutraceutical intervention.” The study on Navelina oranges is a prime example. While the results were modest, the direction of the change—a shift toward an anti-inflammatory profile—points to the power of polyphenols.

Polyphenols are bioactive compounds found in plants that act as signaling molecules in the body. In the context of MASLD, these compounds may help “switch off” the pathways that lead to hepatic steatosis (fat accumulation in the liver).

Why Specificity Matters

Not all oranges are created equal. The focus on the “Navelina” variety highlights a growing trend in agricultural precision. Future trends will likely involve “functional foods” bred or selected for higher concentrations of specific metabolites that target liver enzymes or insulin sensitivity.

Pro Tip: If you’re looking to support your liver health today, focus on “whole-food” polyphenols. Instead of supplements, reach for deep-colored berries, extra virgin olive oil, and citrus fruits. The synergy of fibers and vitamins in whole foods often enhances the absorption of these liver-protecting compounds.

The Gut-Liver Axis: The Next Frontier

One of the most exciting trends in metabolic research is the “Gut-Liver Axis.” We now know that the liver is intimately connected to the gut microbiome via the portal vein.

View this post on Instagram about Liver, Metabolic
From Instagram — related to Liver, Metabolic

When we consume polyphenol-rich foods, they aren’t just digested; they are metabolized by gut bacteria into smaller, more potent molecules. These metabolites then travel directly to the liver, where they can reduce oxidative stress and improve lipid metabolism.

Expect to see a surge in synbiotic diets—combinations of prebiotics (like the fibers in oranges) and probiotics—specifically designed to prime the gut to produce the metabolites the liver needs to heal. For more on this, explore our comprehensive guide to the microbiome.

AI and the Hyper-Personalized Diet

The most significant leap will be the integration of Artificial Intelligence. Imagine an app that syncs your continuous glucose monitor (CGM), your latest lipidomics report, and your genetic predispositions to suggest a daily menu.

For a patient with MASLD, AI might suggest a specific dose of citrus-derived polyphenols on days when inflammatory markers are high, or increase MUFA (monounsaturated fatty acid) intake when LDL patterns shift. This moves us from “preventative” health to “predictive” health.

According to data from global health organizations, metabolic syndrome is rising globally. The scalability of AI-driven nutrition may be the only way to manage this crisis at a population level.

Frequently Asked Questions

Can eating oranges actually cure fatty liver?
While oranges contain beneficial polyphenols that may improve lipid profiles and reduce inflammation, they are not a “cure.” They work best as part of a broader lifestyle intervention including weight management and exercise.

10 Surprising Health Benefits of Eating Oranges Daily

What is the difference between NAFLD and MASLD?
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) is the updated term. It removes the word “alcoholic” (which was seen as stigmatizing) and emphasizes the metabolic drivers of the disease, such as obesity and type 2 diabetes.

What are the best fats for liver health?
Focus on MUFAs (found in olive oil and avocados) and n-3 PUFAs (found in fatty fish and walnuts). These are generally associated with lower liver inflammation compared to saturated trans fats.

Join the Conversation on Metabolic Health

Are you incorporating functional foods into your diet to support your liver? Or are you curious about how lipidomics could change your healthcare? Let us know in the comments below or subscribe to our newsletter for the latest breakthroughs in precision nutrition!

Subscribe for Updates

April 20, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study finds long COVID leaves a distinct immune signature in the blood

by Chief Editor April 15, 2026
written by Chief Editor

Unlocking Long COVID: New Protein Patterns Offer Hope for Diagnosis and Treatment

Recent research is shedding light on the complex biological mechanisms behind Long COVID, identifying distinct protein patterns in the blood that differentiate those still struggling with symptoms months after infection from those who have recovered. A study published in Communications Medicine reveals key inflammatory and neurological markers, offering potential avenues for improved diagnosis and targeted therapies.

The Persistent Puzzle of Long COVID

An estimated 5% to 30% of individuals infected with SARS-CoV-2 experience symptoms lasting months, a condition known as Long COVID. The core question remains: why do some fully recover while others face debilitating fatigue, brain fog, and chronic inflammation? Researchers are increasingly focused on immune dysregulation as a key factor, but identifying reliable biomarkers has proven challenging.

Key Protein Signatures Identified

The study, conducted on participants in Australia, compared blood samples from healthy individuals, those who had recovered from COVID-19, and individuals experiencing Long COVID. Researchers measured 182 inflammatory and neurology-related proteins, pinpointing several that stood out. Elevated levels of interleukin-20 (IL-20), macrophage chemoattractant protein-1 (MCP-1), and neuroblastoma suppressor of tumorigenicity 1 (NBL1) were particularly prominent in individuals with Long COVID, suggesting ongoing inflammation.

Interestingly, even those who had recovered from the initial infection showed some lingering protein differences compared to healthy controls, with fibroblast growth factor 19 (FGF-19) and cystatin D (CST5) associated with recovery status. This suggests that immune alterations can persist even after clinical recovery.

Pro Tip: Understanding these protein signatures could lead to the development of diagnostic tests to identify individuals at risk of developing Long COVID early on, allowing for proactive intervention.

Vaccination and Reinfection: A Shifting Immune Landscape

The research also investigated how vaccination and reinfection impact these protein patterns. Booster doses prompted strong antibody responses in all groups, but individuals with Long COVID and those who had previously recovered exhibited lower spike-specific antibody levels after breakthrough infections compared to those newly infected.

Crucially, the study found that the inflammatory patterns observed after the initial infection were not replicated following reinfection in individuals with Long COVID. This suggests the immune system reacts differently upon subsequent exposure to the virus.

Perhaps most reassuringly, vaccination did not worsen inflammation in individuals with Long COVID. in fact, inflammatory protein levels either stabilized or decreased. This reinforces the importance of vaccination, even for those experiencing long-term symptoms.

Implications for Future Research and Treatment

These findings represent a significant step forward in unraveling the complexities of Long COVID. Identifying these distinct immune alterations opens doors for developing targeted therapies aimed at modulating the immune response and alleviating symptoms. Further research is needed to validate these findings in larger cohorts and explore the potential of these protein markers as diagnostic tools.

The Role of Persistent Viral Presence

Emerging research suggests that the persistence of SARS-CoV-2 RNA or particles in tissues may play a role in driving the chronic inflammation seen in Long COVID. While the exact mechanisms are still being investigated, this persistent viral presence could be triggering ongoing immune dysregulation.

FAQ: Long COVID and Immune Response

Q: What is Long COVID?
A: Long COVID refers to symptoms that persist for weeks or months after the initial SARS-CoV-2 infection.

Q: Are vaccinations safe for people with Long COVID?
A: This study suggests vaccinations are well-tolerated and do not worsen inflammation in individuals with Long COVID.

Q: What are the key symptoms of Long COVID?
A: Common symptoms include fatigue, brain fog, and chronic inflammation.

Q: Can reinfection with SARS-CoV-2 worsen Long COVID?
A: The immune response to reinfection appears different than the initial infection, but this study did not find evidence of worsened inflammation.

Did you know? The number of symptoms associated with Long COVID exceeds 200, highlighting the diverse and individualized nature of the condition.

Wish to learn more about the latest research on Long COVID? Visit the CDC’s Long COVID page for up-to-date information and resources.

Share your experiences with Long COVID in the comments below. What symptoms have you experienced, and how has vaccination impacted your recovery?

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Targeting senescent fat cells provides new hope for ovarian cancer

by Chief Editor April 13, 2026
written by Chief Editor

Ovarian Cancer Treatment: A New Focus on Fat Cells and the Tumor Microenvironment

Ovarian cancer remains a formidable challenge in women’s health, with a low 5-year survival rate for advanced-stage patients – below 30%. Traditional treatments like surgery, chemotherapy, and targeted therapies often fall short, prompting researchers to explore novel approaches. A recent study is shifting the focus from directly attacking cancer cells to targeting the environment that supports their growth, specifically senescent fat cells.

The Role of Senescent Fat Cells in Ovarian Cancer Metastasis

For years, ovarian cancer research has primarily centered on immune cells within the tumor microenvironment (TME). However, emerging evidence highlights the critical role of adipose tissue – fat tissue – and its derived stem cells (ADSCs) in tumor progression. Researchers have observed that adipose tissue near ovarian tumors often exhibits signs of senescence, a state where cells stop dividing but don’t die, instead releasing harmful inflammatory signals.

View this post on Instagram

This senescence isn’t a random occurrence. Ovarian cancer cells actively induce dysfunction and senescence in ADSCs. This process triggers metabolic abnormalities like glucose intolerance and insulin resistance, creating a “permissive niche” for tumor metastasis. The key messengers in this process are extracellular vesicles (OC-EVs) secreted by the cancer cells, which are rich in the pro-inflammatory cytokine IL-1β.

A Vicious Cycle of Inflammation and Senescence

Once OC-EVs interact with ADSCs, they activate the NF-κB signaling pathway. This activation has a dual effect: it pushes ADSCs into a senescent state and promotes the formation of an inflammasome, leading to the release of more inflammatory factors like IL-1β and IL-18. This creates a dangerous “inflammation-senescence” cycle that continuously remodels the TME, fostering tumor growth and spread.

Analysis of clinical samples confirmed a strong correlation between the degree of adipose tissue senescence and tumor progression. Patients with advanced-stage ovarian cancer showed significantly elevated levels of the senescence marker CDKN2A in their adipose tissue.

Targeting Senescence: Promising Therapeutic Strategies

Based on these findings, researchers explored two targeted therapeutic strategies with remarkable results. The first involved the senolytic combination of dasatinib plus quercetin (DQ). In a mouse model, DQ treatment significantly reduced adipose tissue senescence, lowered reactive oxygen species (ROS) levels, improved glucose metabolism and insulin sensitivity, and substantially decreased the number of tumor metastases.

Targeting Senescence: Promising Therapeutic Strategies

The second strategy utilized resveratrol, a natural antioxidant. Resveratrol acts as an NF-κB pathway inhibitor, suppressing ovarian cancer spheroid formation and reversing the senescent phenotype of ADSCs. It too reduces adipose tissue inflammation by inhibiting the NF-κB and MAPK3 signaling pathways. In vivo experiments showed that resveratrol alleviated metabolic disorders, reduced tumor burden, and lowered the risk of intraperitoneal metastasis.

The research team emphasized a core innovation: “We did not directly target cancer cells themselves, but rather cut off the ‘nutrient supply and metastatic routes’ on which tumors rely by regulating senescent adipocytes in the TME.” This approach contrasts with traditional therapies that can damage normal tissue, potentially leading to senescence and tumor recurrence.

Future Directions and Clinical Translation

Both quercetin and resveratrol are naturally occurring compounds with favorable safety profiles, paving the way for clinical translation. Future research will focus on optimizing administration regimens, exploring combination applications with chemotherapy and immunotherapy, and conducting clinical trials to confirm their efficacy in ovarian cancer patients.

Did you know? Targeting senescent cells isn’t limited to ovarian cancer. This approach is being investigated for a range of age-related diseases and cancers.

FAQ

Q: What is senescence?
A: Senescence is a state where cells stop dividing but don’t die, often releasing inflammatory signals that can harm surrounding tissues.

Q: What are senolytics?
A: Senolytics are drugs that selectively eliminate senescent cells.

Q: What is the tumor microenvironment (TME)?
A: The TME is the complex ecosystem surrounding a tumor, including blood vessels, immune cells, and other supporting cells.

Q: Are quercetin and resveratrol readily available?
A: Yes, both are available as dietary supplements, but it’s important to consult with a healthcare professional before starting any new supplement regimen.

Pro Tip: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can help reduce inflammation and support overall health, potentially impacting the tumor microenvironment.

Want to learn more about cutting-edge cancer research? Explore more articles on News-Medical.net.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Natural peptide PEPITEM shows promise in reducing arthritic joint swelling

by Chief Editor April 13, 2026
written by Chief Editor

PEPITEM: A Potential Game-Changer in Arthritis Treatment?

New research suggests a naturally occurring immunopeptide, PEPITEM, could offer a significant advancement in the treatment of inflammatory arthritis, potentially rivaling current standard-of-care options. Scientists at the University of Birmingham, who initially discovered PEPITEM and characterized the Adiponectin-PEPITEM pathway, have demonstrated promising results in both human and animal studies.

Understanding the Adiponectin-PEPITEM Pathway

The Adiponectin-PEPITEM pathway plays a crucial role in regulating immune function and the movement of immune cells throughout the body. This pathway maintains a delicate balance between activating and suppressing the immune system. In a healthy state, adiponectin stimulates white blood cells to produce PEPITEM, which then reduces their migration into tissues, preventing an overactive inflammatory response.

How Arthritis Disrupts the Pathway

In inflammatory arthritis, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA), this natural regulatory process breaks down. White blood cells become less responsive to adiponectin and produce less PEPITEM, leading to uncontrolled inflammation and joint damage. Researchers found a reduced capacity of white blood cells to respond to adiponectin in patients with suspected inflammatory arthritis, a deficiency that could be restored with PEPITEM supplementation.

How Arthritis Disrupts the Pathway

Promising Results from Pre-Clinical and Human Studies

The recent study, published in Arthritis & Rheumatology, investigated the efficacy of PEPITEM in addressing this dysregulation. Results showed that injecting synthetic PEPITEM into animal models of inflammatory and gouty arthritis could prevent the onset of the disease and significantly reduce joint swelling – achieving results comparable to infliximab, a current standard treatment. Tissue analysis revealed less inflammation, cartilage damage, and bone erosion in PEPITEM-treated mice.

Molecular studies further demonstrated that PEPITEM treatment led to a decrease in inflammatory mediators (NF-kB and COX2 protein) and an increase in foxp3, a key component in immune-suppressing white blood cells.

A Safer Alternative?

Professor Helen McGettrick of the University of Birmingham highlights a potential advantage of PEPITEM: “There could be significant benefits over existing therapies, which are immunosuppressive in otherwise healthy populations. The risk of toxicity from a natural peptide is extremely low, and administration in early disease could reduce reliance on steroids in the earliest phases of rheumatoid arthritis and psoriatic arthritis.”

Beyond Arthritis: PEPITEM’s Expanding Potential

This isn’t the first indication of PEPITEM’s broad therapeutic potential. Previous research has suggested its promise in bone repair, enhancing bone mineralisation and strength, and even reversing bone loss. The researchers note that existing Disease-Modifying Anti-Rheumatic Drugs (DMARDs) don’t reverse joint damage, even when inflammation is well-controlled.

Beyond Arthritis: PEPITEM’s Expanding Potential

Future Trends and Implications

The success of PEPITEM in pre-clinical models opens doors for several exciting future trends in arthritis treatment:

  • Early Intervention: PEPITEM’s potential to restore immune regulation suggests it could be particularly effective when administered early in the disease process, potentially preventing irreversible joint damage.
  • Personalized Medicine: Identifying patients with deficiencies in the Adiponectin-PEPITEM pathway could allow for targeted PEPITEM supplementation, maximizing treatment efficacy.
  • Combination Therapies: Exploring the synergistic effects of PEPITEM with existing DMARDs could lead to more comprehensive and effective treatment strategies.
  • Broader Applications: Given PEPITEM’s role in regulating immune function, research may expand to investigate its potential in other autoimmune diseases, such as type 1 diabetes and lupus.

Did you understand?

PEPITEM was initially identified as a protective agent against inflammageing – the chronic, low-grade inflammation associated with aging – suggesting potential benefits beyond arthritis.

FAQ

Q: What is PEPITEM?
A: PEPITEM is a naturally occurring immunopeptide that helps regulate immune function and reduce inflammation.

Q: How does PEPITEM work?
A: PEPITEM reduces the migration of white blood cells into tissues, preventing an overactive inflammatory response.

Q: Is PEPITEM currently available as a treatment?
A: No, PEPITEM is still under investigation and is not yet available as a standard treatment for arthritis.

Q: What types of arthritis could PEPITEM potentially treat?
A: Research suggests PEPITEM could be effective in treating inflammatory arthritis, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Pro Tip: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can support overall immune function and potentially complement future PEPITEM-based therapies.

Stay informed about the latest advancements in arthritis research. Explore more news from the University of Birmingham to learn about ongoing studies and potential breakthroughs.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Lab study shows cigarette smoke damaged lung cells more than e-cigarette vapor

by Chief Editor April 13, 2026
written by Chief Editor

Cigarette Smoke vs. E-Cigarettes: Latest Research Reveals Stark Differences in Lung Cell Damage

A groundbreaking laboratory study published in Scientific Reports has revealed significant differences in how cigarette smoke and e-cigarette vapor affect human lung cells. Researchers at the University of Graz, Austria, found that cigarette smoke extract (CSE) caused substantial disruption to lung cell barriers, triggered inflammation, and damaged DNA, while e-cigarette vapor extract (EVE) showed no significant adverse effects under the same experimental conditions.

The Vulnerable Lung Barrier

Our airway epithelium acts as a crucial defense mechanism, protecting the body from inhaled particles and harmful substances. Cigarette smoke is well-established as a damaging agent to this barrier, contributing to conditions like chronic obstructive pulmonary disease (COPD). The question of whether e-cigarettes pose a similar threat has remained a subject of debate.

View this post on Instagram

This study utilized human Calu-3 lung epithelial cells, meticulously cultured and exposed to CSE and EVE. Researchers assessed barrier integrity, inflammation levels, and DNA damage using a range of sophisticated techniques, including Transwell systems, Western blotting, and DNA strand break assays.

CSE’s Damaging Effects: A Cascade of Cellular Disruption

The results were striking. CSE significantly reduced the electrical resistance of the cell barrier, indicating compromised cell cohesion and increased permeability. So harmful substances could more easily penetrate the lung tissue. CSE decreased the expression of key proteins – claudin-1 and occludin – essential for maintaining the integrity of the apical junctional complex, a critical component of the epithelial barrier. A 45% decline in claudin-1 levels was observed, highlighting its vulnerability to smoke exposure.

Inflammation also surged in cells exposed to CSE, with interleukin-6 (IL-6) levels increasing up to tenfold. Significant DNA damage, indicated by increased DNA strand breaks, was also detected. Notably, the study suggests that the damage caused by cigarette smoke isn’t solely attributable to nicotine, implying other toxic components are at play.

EVE: A Different Story

In stark contrast, EVE did not significantly impact barrier integrity, inflammation, or DNA damage. In some instances, it even appeared to slightly improve barrier stability. This suggests that, under the conditions tested in this in vitro model, e-cigarette vapor exerts less harmful effects on lung epithelial cells compared to cigarette smoke.

What Does This Imply for Public Health?

These findings offer valuable insights into the differing impacts of cigarette smoke and e-cigarette vapor on lung health. While CSE demonstrably disrupts cellular defenses, EVE did not exhibit the same detrimental effects. Though, researchers emphasize that this study was conducted in vitro, meaning in a laboratory setting, and doesn’t directly translate to human health outcomes.

The study used unflavored e-liquid, and the authors acknowledge that the use of liquid extracts rather than direct aerosol exposure may limit the generalizability of the findings. Further research, utilizing more representative biological systems, is crucial to fully understand the long-term health effects of e-cigarette vapor.

Pro Tip: Maintaining a healthy lung barrier is vital for overall respiratory health. Avoiding smoke exposure, whether from cigarettes or other sources, is a key step in protecting your lungs.

Future Trends in Respiratory Research

This study underscores a growing trend in respiratory research: the use of advanced in vitro models, like the Calu-3 cell system, to investigate the effects of inhaled substances. Expect to see more research focusing on:

  • Flavoring Chemicals: The impact of various e-liquid flavoring chemicals on lung cells is an area of increasing concern. Studies are beginning to assess the toxicity of cinnamon, vanilla tobacco, and hazelnut flavors.
  • Long-Term Exposure: Most studies to date have focused on short-term exposure. Longitudinal studies are needed to understand the cumulative effects of e-cigarette vapor over years or decades.
  • Individual Variability: Responses to inhaled substances can vary significantly between individuals. Research is exploring how genetic factors and pre-existing conditions influence susceptibility to lung damage.
  • Air-Liquid Interface (ALI) Models: Utilizing ALI models, which more closely mimic the lung environment, will provide more accurate and relevant data.

FAQ

Q: Does this study mean e-cigarettes are safe?
A: No. This study shows that, under the tested conditions, e-cigarette vapor appeared less harmful than cigarette smoke to lung cells. However, it does not prove e-cigarettes are entirely safe, and long-term effects remain unknown.

Q: What is the Calu-3 cell line?
A: Calu-3 is a human lung adenocarcinoma epithelial cell line commonly used in respiratory research to model lung function and responses to inhaled substances.

Q: What is the apical junctional complex?
A: The apical junctional complex is a protein network that forms a seal between lung epithelial cells, maintaining barrier integrity and preventing harmful substances from entering the body.

Q: What is IL-6?
A: IL-6 is an interleukin, a type of signaling molecule involved in inflammation. Elevated IL-6 levels indicate an inflammatory response.

Want to learn more about lung health and respiratory diseases? Explore our extensive library of articles on News-Medical.net.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

EV-RNAs show promise for IBD diagnosis and treatment

by Chief Editor April 11, 2026
written by Chief Editor

The Future of IBD Treatment: Harnessing the Power of EV-RNAs

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, affects millions worldwide and is projected to impact over 1% of the population in early-industrialized countries by 2045. A recent comprehensive review published in ExRNA, led by researchers at Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, highlights a revolutionary approach to managing this chronic condition: extracellular vesicle-associated RNAs (EV-RNAs).

What are EV-RNAs and Why are They Essential?

EV-RNAs are essentially tiny “biological packages” secreted by cells, containing RNA molecules – including microRNAs and long non-coding RNAs – that act as messengers between cells. These vesicles play a crucial role in regulating the intestinal environment, influencing inflammation, and impacting the gut microbiome. Researchers are discovering that these molecules aren’t just bystanders in IBD, but key regulators that can be targeted for both diagnosis and treatment.

View this post on Instagram

Non-Invasive Diagnosis: A Game Changer

Currently, diagnosing IBD often requires invasive endoscopic examinations. EV-RNAs offer a potential solution with non-invasive biomarkers detectable in easily accessible fluids like plasma and even saliva. Studies cited in the ExRNA review demonstrate remarkably high accuracy – with area under the curve (AUC) values ranging from 0.95 to 0.97 – in distinguishing active IBD from remission using specific EV-RNA signatures, such as elevated levels of long non-coding RNA H19 in plasma EVs.

Pro Tip: The ease of sample collection (saliva, blood) could dramatically improve patient compliance and enable more frequent monitoring of disease activity.

EV-RNA-Based Therapies: Beyond Traditional Approaches

Traditional IBD treatments, like anti-inflammatory drugs and biologics, often come with systemic side effects and can lead to drug resistance. EV-RNA-based therapies offer a more targeted approach. Several strategies are showing promise in preclinical models:

  • Mesenchymal Stem Cell-Derived EVs (MSC-EVs): These EVs carry immunomodulatory miRNAs that can suppress inflammation and promote intestinal barrier repair. They offer a safer alternative to whole-cell stem cell therapy, with a lower risk of immune rejection.
  • Dietary and Plant-Derived EVs: EVs extracted from sources like bovine colostrum, Coptis chinensis, Centella asiatica, and tea contain functional miRNAs that can survive digestion and directly target inflamed intestinal tissues. For example, EVs from Coptis chinensis can restore zinc homeostasis in immune cells, reducing intestinal damage.
  • Engineered EVs: Researchers are modifying EVs to deliver therapeutic RNAs directly to inflamed tissues, offering personalized treatment options for patients who don’t respond to conventional therapies.

Systemic Impact: Addressing Extraintestinal Complications

IBD isn’t limited to the gastrointestinal tract. It’s often associated with complications affecting the liver and heart. The research highlights that EV-RNAs secreted by inflamed intestinal tissues can travel through the bloodstream and influence inflammatory responses in distant organs, providing a molecular link to these systemic issues.

Systemic Impact: Addressing Extraintestinal Complications

Did you know? Understanding the systemic role of gut-derived EV-RNAs could lead to therapies that prevent or mitigate these extraintestinal complications.

Challenges and Future Directions

Despite the exciting potential, several challenges remain. Standardized protocols for EV isolation, purification, and RNA detection are crucial to ensure consistent results across laboratories. Large-scale clinical trials are needed to validate the efficacy of EV-RNA-based diagnostics and therapies in human patients, and clear regulatory pathways for these novel treatments must be established.

Frequently Asked Questions (FAQ)

Q: What is the difference between Crohn’s disease and ulcerative colitis?
A: Crohn’s disease can affect any part of the digestive tract with transmural inflammation, although ulcerative colitis is limited to the colorectal mucosa with superficial inflammation.

Q: Are EV-RNA therapies currently available for IBD patients?
A: No, EV-RNA therapies are still in the preclinical and early clinical stages of development. More research and clinical trials are needed before they become widely available.

Q: How can I learn more about EV-RNA research?
A: You can explore the research published in the journal ExRNA and follow updates from leading research institutions like Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine.

The field of EV-RNA research is rapidly evolving, offering a beacon of hope for the millions affected by IBD. As research progresses and challenges are addressed, these tiny vesicles could revolutionize the way we diagnose, monitor, and treat this debilitating disease.

Want to stay informed about the latest advancements in IBD research? Subscribe to our newsletter for updates and insights from leading experts.

April 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study identifies four radiomic profiles linked to sarcoidosis severity

by Chief Editor April 10, 2026
written by Chief Editor

Revolutionizing Sarcoidosis Diagnosis: How AI-Powered CT Scans Are Changing the Game

For the over 150,000 Americans living with sarcoidosis, a complex inflammatory lung disease, diagnosis and monitoring have long been a challenge. Traditional methods rely on visual assessment of chest CT scans, a process prone to variability between specialists. But a recent era in sarcoidosis care is dawning, powered by radiomics – a cutting-edge technology that uses artificial intelligence to unlock hidden insights within these scans.

What is Radiomics and Why Does It Matter?

Radiomics isn’t about replacing radiologists; it’s about augmenting their expertise. This computer-based imaging technique employs advanced algorithms to measure hundreds of quantitative features from medical images, far beyond what the human eye can discern. These features capture subtle patterns in lung tissue, providing a multidimensional characterization of the disease.

View this post on Instagram

“We found that radiomic analysis of CT scans can reveal distinct patterns of lung abnormalities in sarcoidosis,” explains Tasha Fingerlin, PhD, of National Jewish Health. “These patterns were associated with differences in lung function, suggesting that this approach may help us better understand how the disease varies from patient to patient.”

Four Distinct Profiles: Unlocking Sarcoidosis Subtypes

Researchers at National Jewish Health, analyzing CT scans from 320 sarcoidosis patients as part of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study, have identified four distinct imaging profiles. These profiles range from patients with minimal lung abnormalities to those exhibiting patterns indicative of significant inflammation or fibrosis. Crucially, these radiomic groups correlated with differences in lung function, even after accounting for traditional imaging assessments.

This discovery is significant because current staging systems, while helpful, don’t always capture the full complexity of the disease. Radiomics offers a more detailed and reproducible way to quantify these patterns.

Beyond Diagnosis: Tracking Disease Progression and Personalizing Treatment

The potential of radiomics extends far beyond initial diagnosis. Because the analysis can be performed quickly and automatically using open-source software, it could enable clinicians to analyze large numbers of scans and track disease patterns over time with unprecedented efficiency.

“Radiomics has the potential to complement the expertise of radiologists by providing objective measurements of lung abnormalities, identifying disease subtypes, monitoring progression and potentially guiding more personalized treatment strategies,” says Dr. Fingerlin.

Lisa Maier, MD, adds that this technology could be particularly impactful in areas lacking specialized sarcoidosis expertise. “There is promise for significant impact on patient care, especially in regions where there is no expert in sarcoidosis radiology… Radiomics could also expedite care in clinics with rapid turnaround for patients at specialized centers and revolutionize the way we interpret CT scans for research and clinical trials.”

The Future of AI in Pulmonary Imaging

The development of radiomic profiling represents a broader trend: the increasing integration of AI into pulmonary imaging. Expect to observe further advancements in this field, including:

  • Predictive Modeling: AI algorithms could predict which patients are most likely to experience disease progression or respond to specific treatments.
  • Automated Reporting: AI-powered tools could generate preliminary reports for radiologists, streamlining the workflow and reducing the risk of errors.
  • Integration with Other Data Sources: Combining radiomic data with genomic information, patient history, and other clinical data could provide a holistic view of the disease.

FAQ

What is sarcoidosis? Sarcoidosis is a complex inflammatory lung disease that affects more than 150,000 people in the United States.

What is radiomics? Radiomics is a computer-based imaging technique that analyzes subtle patterns in medical images using advanced algorithms.

How does radiomics improve sarcoidosis diagnosis? Radiomics provides a more objective and reproducible way to assess lung abnormalities, identifying distinct patterns linked to disease severity and lung function.

Is radiomics widely available? While still an emerging technology, radiomics is becoming increasingly accessible thanks to open-source software and growing research efforts.

Will AI replace radiologists? No, radiomics is designed to augment the expertise of radiologists, not replace them.

Did you know? National Jewish Health is a WASOG (World Association of Sarcoidosis and Granulomatous Disease) Center of Excellence for Sarcoidosis, a designation it has held since 2017.

Pro Tip: Early and accurate diagnosis is crucial for effective sarcoidosis management. Discuss the potential benefits of radiomic analysis with your healthcare provider.

Want to learn more about the latest advancements in lung disease research? Explore our other articles on pulmonary health and innovative diagnostic techniques.

April 10, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

Six-week boxing routine lowers blood pressure in young adults

by Chief Editor March 28, 2026
written by Chief Editor

Boxing Beyond the Ring: A New Prescription for Heart Health?

A surprising new ally in the fight against hypertension is emerging: the boxing gym. Recent research from The University of Texas at El Paso reveals that just six weeks of boxing training can significantly lower blood pressure and improve cardiovascular health in young adults with elevated blood pressure or Stage 1 hypertension.

The Science Behind the Punch

The study, published in the journal Sports, involved 24 participants around 25 years vintage, none of whom were regular exercisers. Half engaged in a six-week boxing program, while the other half followed a general exercise routine. The boxing regimen consisted of 10 three-minute rounds with one-minute rests, designed to push participants to both maximum and moderate cardiovascular exertion.

The results were striking. Boxing participants experienced an average drop of approximately 16 mmHg in systolic blood pressure and 10 mmHg in diastolic blood pressure – comparable to the effects often achieved with medication. Beyond simply lowering numbers, the training also improved blood vessel function, increasing their responsiveness and ability to regulate blood flow.

How Does Boxing Benefit the Heart?

Researchers pinpoint several key mechanisms at play. Boxing training appears to boost nitric oxide levels by 27%, a compound known to relax blood vessels. Simultaneously, it reduced levels of C-reactive protein, a marker of cardiovascular risk. The combination of high-intensity bursts and brief recovery periods challenges the cardiovascular system, while the repetitive impact strengthens vessel walls.

“The results demonstrate that boxing training is not simply a fun way to exercise; it has a tangible impact on how your blood vessels operate,” explained Dr. Alvaro Gurovich, lead author of the study and chair of the Department of Physical Therapy and Movement Sciences at UTEP.

Limitations and Future Research

While promising, the study wasn’t without limitations. The six-week timeframe was relatively short, and some arterial stiffness measures didn’t show immediate improvement. All participants were young adult males, limiting the generalizability of the findings. The control group also demonstrated lower compliance with their exercise program, potentially influencing the results. Researchers also did not comprehensively examine the diets of the participants.

Future research will likely focus on expanding the study to include diverse populations, investigating longer-term effects, and exploring optimal training protocols. Researchers are also interested in understanding how boxing training might interact with existing hypertension medications.

Beyond Blood Pressure: The Wider Implications

The findings have broader implications for preventative healthcare. Hypertension is a leading cause of heart disease and stroke, often remaining undetected in young adults. Exercise is a cornerstone of hypertension management, but finding engaging and effective methods remains a challenge. Boxing offers a potentially appealing and impactful option.

“Individuals with early signs of hypertension are still exposed to the same levels of risk that individuals with a diagnosis of hypertension experience,” researchers noted. “Many young adults experience a ‘grey area.’ exercise is the main focus for their treatment, while the effects of medication may not be beneficial.”

Could Boxing Become a Mainstream Therapy?

While it’s too early to declare boxing a universal prescription, the evidence suggests it deserves serious consideration. The unique combination of cardiovascular challenge, strength training, and stress relief could make it a valuable tool in the fight against heart disease. As Dr. Scott Kruse, Dean of the College of Health Sciences at UTEP, stated, “The results of this research exemplify the type of practical, applied science that our college stands for.”

FAQ

Q: How long does it take to observe results from boxing training?
A: This study showed significant results after just six weeks.

Q: Is boxing safe for people with high blood pressure?
A: It’s crucial to consult with a doctor before starting any new exercise program, especially if you have pre-existing health conditions.

Q: Do I need to be an experienced boxer to benefit?
A: No. This study involved participants with no prior boxing experience.

Q: What type of boxing training was used in the study?
A: Participants engaged in heavy-bag training, consisting of 10 three-minute rounds with one-minute rests.

March 28, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Why are older adults far more at risk from COVID or flu?

by Chief Editor March 28, 2026
written by Chief Editor

Aging Lungs: The Hidden Link to Severe Flu and COVID-19

For years, scientists have known older adults face a significantly higher risk of severe illness from respiratory infections like influenza and COVID-19. Now, groundbreaking research from the University of California, San Francisco (UCSF) sheds light on why. The culprit? Aging lung cells, specifically fibroblasts, triggering an excessive immune response.

Inflammaging: A New Understanding of Age-Related Illness

The study, published in the journal Immunity, identifies a process called “inflammaging” – chronic, low-grade inflammation associated with aging – as a key driver of severe respiratory illness. Researchers discovered that aging lung fibroblasts send out distress signals that activate the immune system, leading to clusters of inflamed cells. These clusters contain cells marked by the GZMK gene, previously linked to severe COVID-19 cases.

“We were surprised to see lung fibroblasts working hand-in-hand with immune cells to drive inflammaging,” explains Dr. Tien Peng, a professor of medicine at UCSF and senior author of the paper. “It suggests new ways to intervene before patients progress to severe inflammation that can require intubation.”

How the Study Uncovered the Connection

To understand the role of fibroblasts, researchers engineered young mice’s lung cells to mimic the distress signals of aging lungs. This resulted in an immune response and the formation of inflamed cell clusters, mirroring what’s seen in aging lungs. Crucially, removing the GZMK-positive cells allowed the young lungs to better withstand infection.

Further investigation of lung tissue from older COVID-19 patients revealed the same inflamed cell clusters, with sicker patients exhibiting a greater concentration. This confirms that aging lung tissue itself can drive harmful inflammation, rather than simply being a passive bystander.

Beyond COVID-19: Implications for Other Lung Diseases

The implications of this research extend beyond COVID-19 and influenza. Fibroblasts are also implicated in other lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD). Understanding how these cells contribute to inflammation could lead to new therapeutic strategies for a range of respiratory conditions.

Researchers observed that even after the initial COVID-19 infection subsided, persistent lung inflammation remained in vulnerable patients. This suggests a dysfunctional circuit between lung and immune cells, offering a promising new target for treatment.

Future Therapies: Targeting Inflammation at the Source

The findings open the door to potential therapies that directly target the GZMK cells or interrupt the signaling pathways that drive inflammaging. A future therapy could potentially slow age-related inflammation and protect older adults from severe respiratory illness.

What Does This Mean for the Future of Respiratory Health?

This research represents a significant shift in our understanding of why older adults are more vulnerable to respiratory infections. It moves the focus from solely addressing the virus itself to tackling the underlying inflammatory processes within the lungs.

FAQ

Q: What are fibroblasts?
A: Fibroblasts are structural cells found in the lungs and other tissues, providing support and maintaining tissue integrity.

Q: What is inflammaging?
A: Inflammaging is the chronic, low-grade inflammation that accumulates with age, contributing to various age-related diseases.

Q: Is this research applicable to other respiratory illnesses?
A: Yes, the findings have implications for understanding and treating other lung diseases, such as COPD.

Q: When might we see new treatments based on this research?
A: While it’s tricky to predict a specific timeline, researchers are actively exploring potential therapeutic targets based on these findings.

Did you know? The GZMK gene, identified in this study, was previously associated with severe COVID-19 cases, highlighting the importance of understanding its role in lung inflammation.

Pro Tip: Maintaining a healthy lifestyle, including regular exercise and a balanced diet, can help reduce overall inflammation and support lung health as you age.

Want to learn more about respiratory health and the latest research? Explore our other articles on lung disease prevention and aging and immunity.

Share your thoughts! What are your biggest concerns about respiratory health as you age? Exit a comment below.

March 28, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Do multi-strain probiotics improve long covid symptoms?

by Chief Editor March 27, 2026
written by Chief Editor

Can Probiotics Offer a Path to Long COVID Relief? Emerging Research Explores Gut-Brain Connection

The lingering effects of COVID-19, often referred to as long COVID, continue to challenge medical science. While research expands, a growing body of evidence suggests a surprising potential ally in the fight against persistent symptoms: probiotics. New studies are focusing on the gut microbiome and its intricate relationship with the immune system, inflammation and even cognitive function in individuals experiencing long COVID.

The Gut-COVID Connection: Why the Microbiome Matters

The gut microbiome – the trillions of bacteria, fungi, and other microorganisms residing in our digestive tract – plays a crucial role in overall health. It influences immune responses, nutrient absorption, and even mental wellbeing. Emerging research indicates that SARS-CoV-2 infection can disrupt this delicate balance, leading to gut dysbiosis, a state of microbial imbalance. This disruption is thought to contribute to the wide range of symptoms associated with long COVID.

Inflammation, a hallmark of both acute COVID-19 and its long-term effects, is closely linked to gut health. A compromised microbiome can exacerbate inflammation, potentially fueling the persistent symptoms experienced by many long COVID sufferers. Modulating the gut microbiome through interventions like probiotics is therefore being explored as a potential therapeutic strategy.

Recent Findings: Modest Shifts, Promising Signals

A recent study published in Microorganisms investigated the impact of a multi-strain probiotic intervention on individuals with long COVID. Researchers found that the probiotic blend – containing Saccharomyces boulardii, Lacticaseibacillus rhamnosus GG, and two Lactiplantibacillus plantarum strains – induced selective changes in the gut microbiome. Specifically, certain beneficial bacterial genera, like Adlercreutzia and Ruminococcaceae, increased in abundance, while potentially harmful bacteria, such as Prevotella_9, decreased.

While these changes weren’t dramatic, they were statistically significant in some cases and aligned with patterns observed in individuals recovering from acute COVID-19. Functional prediction analysis suggested the probiotics might improve bacterial energy metabolism and reduce oxidative stress. Trends toward reduced inflammation and improved liver biomarkers were also observed, though these were not statistically significant.

Beyond Lactobacillus and Bifidobacterium: The Rise of Multi-Strain Approaches

Traditionally, probiotics featuring Lactobacillus and Bifidobacterium have been the focus of gut health research. However, the latest studies suggest that a broader approach, incorporating strains like Saccharomyces boulardii, may be more effective in addressing the complex challenges of long COVID. S. Boulardii is known for its anti-inflammatory and gut-protective properties, offering a complementary mechanism of action.

Synbiotics and the Future of Long COVID Treatment

The concept of “synbiotics” – combining probiotics with prebiotics (fibers that feed beneficial bacteria) – is gaining traction as a potentially more powerful approach to restoring gut health. Research published in The Lancet suggests that synbiotics could offer a new treatment framework for post-acute COVID-19 syndrome. By providing both the beneficial bacteria and the fuel they need to thrive, synbiotics may offer a more sustainable and effective solution.

Fatigue, Memory Loss, and the Microbiome: Emerging Evidence

Some of the most debilitating symptoms of long COVID include fatigue and cognitive dysfunction, often referred to as “brain fog.” Interestingly, recent studies indicate a link between gut health and these neurological symptoms. Probiotics have shown promise in reducing fatigue and improving memory in some long COVID patients, potentially by modulating the gut-brain axis – the bidirectional communication pathway between the gut microbiome and the central nervous system.

Pro Tip:

Don’t self-treat. Always consult with a healthcare professional before starting any new supplement regimen, especially if you have underlying health conditions.

Challenges and Future Directions

Despite the promising findings, research on probiotics and long COVID is still in its early stages. Many studies are limited by small sample sizes, non-randomized designs, and the use of functional prediction analysis rather than direct measurement of microbial activity. Larger, well-controlled clinical trials are needed to confirm these initial findings and determine the optimal probiotic strains, dosages, and treatment durations.

personalized approaches may be crucial. The gut microbiome is highly individual, and the most effective probiotic intervention may vary depending on a person’s specific microbial profile and symptom presentation.

FAQ: Probiotics and Long COVID

  • Can probiotics cure long COVID? No, probiotics are not a cure for long COVID, but they may help manage some symptoms.
  • Which probiotic strains are best for long COVID? Multi-strain probiotics containing Saccharomyces boulardii, Lacticaseibacillus rhamnosus GG, and Lactiplantibacillus plantarum strains show promise.
  • How long does it take to see results? The timeframe for seeing results can vary, but studies typically involve a 12-week intervention period.
  • Are there any side effects of taking probiotics? Probiotics are generally safe for most people, but some may experience mild digestive discomfort.

Did you know? The gut microbiome is as unique as a fingerprint, varying significantly from person to person.

The exploration of probiotics as a potential therapeutic strategy for long COVID represents a fascinating intersection of gut health, immunology, and neurology. While more research is needed, the emerging evidence suggests that nurturing the gut microbiome may offer a valuable tool in the ongoing effort to alleviate the burden of this complex and challenging condition.

Want to learn more about gut health and its impact on overall wellbeing? Explore our other articles on microbiome research and the gut-brain connection.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Cellular All-Clear Signal Restarts Protein Synthesis

    May 14, 2026
  • MLS Gehaltsreport 2026: Wie viel verdienen Ex-DFB-Stars wie Müller, Reus & Co. in den USA?

    May 14, 2026
  • Plasticizers and Lymphoma Risk: How to Identify and Reduce Exposure

    May 14, 2026
  • UGent Accelerates Withdrawal From Israel Projects Amid Activist Pressure

    May 14, 2026
  • Russia Claims US-Israel Attacks Aim to Block Iran-Arab Normalization

    May 14, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World